Achievement of Lipid Targets with the Combination of Rosuvastatin and Fenofibric Acid in Patients with Type 2 Diabetes Mellitus

Achievement of Lipid Targets with the Combination of Rosuvastatin and Fenofibric Acid in Patients with Type 2 Diabetes Mellitus

  • نوع فایل : کتاب
  • زبان : انگلیسی
  • مؤلف : Robert S. Rosenson , Dawn M. Carlson , Maureen T. Kelly , Carolyn M. Setze , Boaz Hirshberg , James C. Stolzenbach , Laura A. Williams
  • چاپ و سال / کشور: 2010

Description

Objective The objective of this study was to assess the proportion of patients with type 2 diabetes mellitus (T2DM) attaining individual and combined targets of low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), non-HDL-C, and apolipoprotein B (ApoB) after treatment with rosuvastatin (R) + fenofibric acid (FA) compared with correspondingdose R monotherapy. Methods This post hoc analysis evaluated data from the T2DM subset of patients with mixed dyslipidemia (LDL-C .130 mg/dL, HDL-C <40/50 mg/dL in men/ women, and TG .150 mg/dL) from 2 randomized studies. Patients included in the analysis (N=456) were treated with R (5, 10, or 20 mg), FA 135 mg, or R (5, 10, or 20 mg) + FA 135 mg for 12 weeks. Attainment of LDL-C <100 mg/dL, HDL-C >40/50 mg/dL in men/women, TG <150 mg/dL, non- HDL-C <130 mg/dL, ApoB <90 mg/dL, and the combined targets of these parameters was assessed. Results Treatment with R + FA resulted in a significantly higher proportion of patients achieving optimal levels of HDL-C (46.8% vs. 20.8%, P=0.009 for R 10 mg + FA), TG (60.0% vs. 34.0%, P=0.02 for R 10 mg + FA; 54.0% vs. 26.4%, P=0.005 for R 20 mg + FA), non-HDL-C (55.1% vs. 36.4%, P=0.04 for R 5 mg + FA), ApoB (58.0% vs. 36.4%, P=0.02 for R 5 mg + FA); and the combined targets of LDL-C, HDL-C, and TG (28.3% vs. 8.3%, P= 0.02 for R 10 mg + FA) and all 5 parameters (26.1% vs. 8.3%, P=0.03 for R 10 mg + FA) than corresponding-dose R monotherapies. Conclusions A significantly greater proportion of T2DM patients achieved individual and combined lipid targets when treated with the combination of R + FA than corresponding-dose R monotherapies
Cardiovasc Drugs Ther (2011) 25:47–57 Published online: 21 December 2010
اگر شما نسبت به این اثر یا عنوان محق هستید، لطفا از طریق "بخش تماس با ما" با ما تماس بگیرید و برای اطلاعات بیشتر، صفحه قوانین و مقررات را مطالعه نمایید.

دیدگاه کاربران


لطفا در این قسمت فقط نظر شخصی در مورد این عنوان را وارد نمایید و در صورتیکه مشکلی با دانلود یا استفاده از این فایل دارید در صفحه کاربری تیکت ثبت کنید.

بارگزاری